$ATON: $ATON Just Dropped a $46M NVIDIA Deal at JPM — The Biotech-to-AI Pivot is Real.

Hey everyone, If you haven't been watching AlphaTON Capital ($ATON) (formerly Portage Biotech), they just made a massive announcement today during JPM week that basically completes their transformation into an AI infrastructure play. The stock has been volatile lately, but the numbers they just released for their "AI Compute" transition are pretty eye-opening. 1. The $46M NVIDIA Deal: ATON officially closed a deal for 576 NVIDIA B300 chips (a half-cluster). • The Math: They are projecting a 27% IRR and a 282% ROI on this hardware. • The Cash Flow: They expect this cluster to return $53.6 million in cash over the next 5 years. • Timeline: Chips arrive in Feb, fully deployed in March 2026. Revenue starts hitting the books in Q1/Q2. 2. The Financials (Cash vs. Debt): A lot of people were worried about their balance sheet after the pivot. Here’s where they stand as of this morning: • Current Treasury: ~$28.6M - $30M in cash and digital assets (TON/USD1). • Smart Debt: They used $32.7M in non-recourse debt to fund the NVIDIA chips. This is key—the debt is tied to the hardware itself, not the whole company, and they don't start paying interest until the chips are actually generating revenue in March. • Burn Rate: By shifting to "AlphaTON Health" and pausing expensive legacy trials, they’ve slashed their overhead. 3. What happened to the Biotech? They aren't "abandoning" it, they are retooling it: • They’ve set aside $4M for "AlphaTON Health" to manage legacy assets (like the Adenosine program). • The goal is to use their own AI compute power to run drug-repurposing models for rare cancers, then partner them out rather than paying for the trials themselves. 4. The "Own Your Node" Program: This is the "retail" angle. They are launching a way for individual investors to buy "fractional" ownership of these GPUs. Basically, you can own a piece of the AI infrastructure powering the Telegram ecosystem and get a cut of the yield. My Take: It’s a high-risk, high-reward pivot. Moving from a burning biotech clinical trial model to a revenue-generating AI infrastructure model is a bold move. If they actually hit that $53M revenue projection from the new chips, the current market cap looks undervalued compared to other AI infrastructure peers.